Last reviewed · How we verify
AMMONIA N 13
AMMONIA N 13 is a marketed small molecule with a specific mechanism of action, currently positioned in the market without a clearly defined primary indication or revenue data. The key strength of AMMONIA N 13 lies in its unique mechanism of interaction with a specific target in the body, which differentiates it from other treatments. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | AMMONIA N 13 |
|---|---|
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 2007 |
Approved indications
Common side effects
Key clinical trials
- Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET (PHASE2)
- Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)
- Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMMONIA N 13 CI brief — competitive landscape report
- AMMONIA N 13 updates RSS · CI watch RSS